Skip to main content
. 2016 Jun 7;7(29):45214–45224. doi: 10.18632/oncotarget.9901

Figure 2. Cyclin D1 controls the sensitivity of cells to carfilzomib.

Figure 2

(A) GFP-expressing Cl7 and D1-GFP-expressing Cl4, either in suspension or in co-cultures with HS-5 cells, were treated with 1 μM pomalidomide (P) or with vehicle, as a control, for 72 h. The cells were then treated with 50 nM (C50) or 100 nM (C100) carfilzomib for 1 h and further cultured for 24 h. The cells were then stained with anti-APO2.7 Ab and analyzed by flow cytometry. At least, 2 × 104 events were gated for each culture condition. The mean of four independent experiments is indicated in the graph together with the SD. (B) CAM-DR was calculated by the formula: percentage of APO2.7-positive cells in co-culture on HS-5 cells/percentage of APO2.7-positive cells in suspension. The mean ± SD of four independent experiments is indicated in the graph. *p < 0.05 with the t-test.